At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 46 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Placebo 0.7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients on Highly Active Antiretroviral Therapy (HAART)
In Brief
A Phase 4 clinical trial evaluating Placebo and Genotropin (human recombinant Growth hormone) for HIV Infections and Lipodystrophy. Completed, enrolled 46 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the effect of low-dose human growth hormone therapy on immune status and fat morphology.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Lipodystrophy
CountriesDenmark
CollaboratorsPfizer
Timeline
Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2005
First PostedJul 2005
Primary CompletionMay 2007
Study CompletionJul 2008
TodayJul 2026
First PostedJul 14, 2005
Enrollment StartFeb 1, 2005
Primary CompletionMay 1, 2007
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 21.0 years ago
Interventions
Placebodrug
Placebo, 0.7 mg/day injected subcutaneously
Genotropin (human recombinant Growth hormone)drug
Genotropin, 0.7 mg/day injected subcutaneously